GFAP and myeloid sarcoma: Both GFAP and sTREM-2 CSF and serum levels have been correlated with clinical disability and neuroradiological activity in MS [8,12,13,14]; moreover, serum levels of GFAP have been associated with a progressive course, higher EDSS, older age, longer disease duration [15].